BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36200418)

  • 1. Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation.
    Tassi E; Noviello M; De Simone P; Lupo-Stanghellini MT; Doglio M; Serio F; Abbati D; Beretta V; Valtolina V; Oliveira G; Racca S; Campodonico E; Ruggiero E; Clerici D; Giglio F; Lorentino F; Dvir R; Xue E; Farina F; Oltolini C; Manfredi F; Vago L; Corti C; Bernardi M; Clementi M; Brix L; Ciceri F; Peccatori J; Greco R; Bonini C
    Haematologica; 2023 Jun; 108(6):1530-1543. PubMed ID: 36200418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
    Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
    Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
    Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
    Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
    Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation.
    Borchers S; Bremm M; Lehrnbecher T; Dammann E; Pabst B; Wölk B; Esser R; Yildiz M; Eder M; Stadler M; Bader P; Martin H; Jarisch A; Schneider G; Klingebiel T; Ganser A; Weissinger EM; Koehl U
    PLoS One; 2012; 7(12):e50248. PubMed ID: 23272059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.
    Gratama JW; van Esser JW; Lamers CH; Tournay C; Löwenberg B; Bolhuis RL; Cornelissen JJ
    Blood; 2001 Sep; 98(5):1358-64. PubMed ID: 11520783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation.
    Moins-Teisserenc H; Busson M; Scieux C; Bajzik V; Cayuela JM; Clave E; de Latour RP; Agbalika F; Ribaud P; Robin M; Rocha V; Gluckman E; Charron D; Socié G; Toubert A
    J Infect Dis; 2008 Sep; 198(6):818-26. PubMed ID: 18666855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
    Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.
    Tey SK; Kennedy GA; Cromer D; Davenport MP; Walker S; Jones LI; Crough T; Durrant ST; Morton JA; Butler JP; Misra AK; Hill GR; Khanna R
    PLoS One; 2013; 8(10):e74744. PubMed ID: 24146744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation.
    Horowitz A; Guethlein LA; Nemat-Gorgani N; Norman PJ; Cooley S; Miller JS; Parham P
    J Immunol; 2015 Nov; 195(9):4524-36. PubMed ID: 26416275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
    Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
    Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation--a comparison of different assays for the detection of cytomegalovirus-specific T cells.
    Abu-Khader A; Krause S
    Eur J Haematol; 2013 Dec; 91(6):534-45. PubMed ID: 23952609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation.
    Liu J; Chang YJ; Yan CH; Xu LP; Jiang ZF; Zhang XH; Liu KY; Huang XJ
    J Infect; 2016 Sep; 73(3):261-70. PubMed ID: 27311748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.
    Cwynarski K; Ainsworth J; Cobbold M; Wagner S; Mahendra P; Apperley J; Goldman J; Craddock C; Moss PA
    Blood; 2001 Mar; 97(5):1232-40. PubMed ID: 11222365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.
    Ciáurriz M; Beloki L; Zabalza A; Bandrés E; Mansilla C; Pérez-Valderrama E; Lachén M; Rodríguez-Calvillo M; Ramírez N; Olavarría E
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells.
    Ozdemir E; St John LS; Gillespie G; Rowland-Jones S; Champlin RE; Molldrem JJ; Komanduri KV
    Blood; 2002 Nov; 100(10):3690-7. PubMed ID: 12393402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible Impact of Cytomegalovirus-Specific CD8
    Ogonek J; Varanasi P; Luther S; Schweier P; Kühnau W; Göhring G; Dammann E; Stadler M; Ganser A; Borchers S; Koehl U; Weissinger EM; Hambach L
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1046-1053. PubMed ID: 28344058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
    Gondo H; Himeji D; Kamezaki K; Numata A; Tanimoto T; Takase K; Aoki K; Henzan H; Nagafuji K; Miyamoto T; Ishikawa F; Shimoda K; Inaba S; Tsukamoto H; Horiuchi T; Nakashima H; Otsuka T; Kato K; Kuroiwa M; Higuchi M; Shibuya T; Kamimura T; Kuzushima K; Tsurumi T; Kanda Y; Harada M
    Int J Hematol; 2004 Dec; 80(5):441-8. PubMed ID: 15646657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
    Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
    Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.